Multifunctional nanoparticle compositions and uses thereof
Disclosed herein are multifunctional nanoparticle compositions. The compositions can be useful for the treatment of cancer by enhancing the anti-tumor effectiveness of radiation directed to a tissue, cell or a tumor and the methods of use thereof. The multifunctional nanoparticle composition comprises a metal oxide nanoparticle core; a functional coating on the surface of the metal oxide nanoparticle core; and a matrix carrier in which the coated nanoparticle is embedded.
1. A multifunctional nanoparticle pharmaceutical liquid suspension composition comprising (a) multiple coated nanoparticles that in the presence of H 2 O 2 produce O 2 , each coated nanoparticle comprising one or more manganese dioxide nanoparticle (MD NP), each MD NP being coated with a cationic polyelectrolyte layer and a layer of oleic acid covalently attached to the cationic polyelectrolyte, the multiple coated nanoparticles being embedded in a solid lipid matrix, and (b) a pharmaceutically acceptable vehicle, and wherein the multifunctional nanoparticle is formulated for intravenous or intraarterial administration.
2. The pharmaceutical composition of claim 1 , wherein the multiple coated nanoparticles embedded in the matrix further comprise a functional moiety.
3. The pharmaceutical composition of claim 2 , wherein the functional moiety is selected from the group consisting of a targeting moiety, a detectable moiety, a chemiluminescent molecule, fluorescent molecule, an electrochemiluminescent molecule, a contrast agent, a chelating agent, and the mixtures thereof.
4. The pharmaceutical composition of claim 1 , wherein the multiple coated nanoparticle further comprises a functional coating selected from the group consisting of a biocompatibility coating, a colloidal coating, an organic coating, an inorganic coating, a hydrophilic coating, and mixtures thereof.
5. The pharmaceutical composition of claim 1 , wherein the polyelectrolyte layer is poly(allylamine hydrochloride) (PAH) layer.
6. The pharmaceutical composition of claim 5 , wherein the matrix comprises albumin.
7. The pharmaceutical composition of claim 1 , wherein the solid lipid matrix comprises a lipid-PEG.
8. The pharmaceutical composition of claim 1 , wherein the solid lipid matrix comprises a myristic acid and a PEG-lipid.
9. The pharmaceutical composition of claim 1 , wherein the multifunctional nanoparticle composition is negative charged.
10. A method of preparing a multifunctional nanoparticle composition having reduced cytotoxicity for in vivo applications and the multifunctional nanoparticle in the composition produce O 2 in the presence of H 2 O 2 , the method comprising the steps of:
(a) mixing an aqueous solution of KMnO 4 metal oxide with a polyelectrolytethereby obtaining a polyelectrolyte-stabilized manganese dioxide (MnO 2 ) nanoparticle precursors, wherein the polyelectrolyte is poly(allylamine hydrochloride) (PAH) or polyarginine, and when the polyelectrolyte is PAH, then a molar ratio between PAH and KMnO 4 is about 2:1;
(b) purifying the polyelectrolyte-stabilized MnO 2 nanoparticle precursors;
(c) covalently linking oleic acid molecules to the surface of the purified polyelectrolyte-stabilized MnO 2 nanoparticles by mixing the purified polyelectrolyte-stabilized MnO 2 nanoparticles with oleic acid molecules and adding an organic phase to the mixture to obtain an aqueous dispersion of hydrophobic oleic acid conjugate-MnO 2 (oMnO 2 ) nanoparticles;
(d) isolating the hydrophobic oMnO 2 nanoparticles from the aqueous dispersion; and
(e) loading the isolated hydrophobic oMnO 2 nanoparticles in a solid lipid matrix to form a particle loaded with one or more oMnO 2 nanoparticles thereby preparing the multifunctional nanoparticle composition.
11. The method of claim 10 further comprising a step of treating the particle loaded with one or more functional MnO 2 nanoparticles with a functional moiety to form functional loaded particles.
12. The method of claim 10 , wherein the polyelectrolyte is polyarginine.
13. The method of claim 10 , wherein step (b) comprises purifying the MnO 2 nanoparticle precursor with ultracentrifugation at between about 10,000 and about 50,000 revolutions per minute for between about 10 mins and 1 hour to remove unreacted PAH or polyarginine.